Neo-Mercazole (Carbimazole)

Carbimazole is converted in the body to methimazole, which inhibits thyroid peroxidase. This enzyme is essential for iodination of thyroglobulin and the coupling reactions that produce T3 and T4. By blocking these steps, carbimazole reduces the synthesis and release of thyroid hormones.

The dose of Neo-Mercazole is individualized by the prescribing clinician based on the severity of hyperthyroidism, patient age, weight and response to therapy. Dosage is adjusted according to regular monitoring of thyroid function tests to achieve target hormone levels.

Safety data for carbimazole in pregnancy and lactation are limited. It may be used only when the potential benefit to the mother outweighs possible risks to the fetus or infant. Physicians should discuss the risk‑benefit profile with the patient and consider alternative management when appropriate.

To order Neo-Mercazole, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to carbimazole is propylthiouracil (PTU). Both inhibit thyroid hormone synthesis, but PTU also blocks peripheral conversion of T4 to T3. Carbimazole is generally preferred for long‑term management because of a more favorable safety profile, whereas PTU is reserved for specific situations such as the first trimester of pregnancy.

Neo-Mercazole should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain potency. Keep out of reach of children and do not use if the packaging is damaged.

Neo-Mercazole is taken orally, usually once daily or in divided doses as directed by the prescriber. Tablets should be swallowed whole with water and can be taken with or without food. Consistency in timing helps maintain stable drug levels.

Serious adverse events include agranulocytosis, severe liver injury, vasculitis, aplastic anemia and, rarely, thyroid storm. Patients should be instructed to report symptoms such as fever, sore throat, jaundice, unexplained rash or severe fatigue promptly, as these may signal life‑threatening complications.

Neo-Mercazole is contraindicated in patients with known hypersensitivity to carbimazole or methimazole, those with existing severe bone‑marrow suppression, and individuals who are pregnant or breastfeeding unless the clinical benefit justifies potential risks. Caution is also advised for patients with liver disease or a history of vasculitis.